Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 38

1.

Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial.

Marks WJ Jr, Ostrem JL, Verhagen L, Starr PA, Larson PS, Bakay RA, Taylor R, Cahn-Weiner DA, Stoessl AJ, Olanow CW, Bartus RT.

Lancet Neurol. 2008 May;7(5):400-8. doi: 10.1016/S1474-4422(08)70065-6. Epub 2008 Apr 2.

PMID:
18387850
2.

Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial.

Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor PA, Bland RJ, Young D, Strybing K, Eidelberg D, During MJ.

Lancet. 2007 Jun 23;369(9579):2097-105.

PMID:
17586305
3.

Hippocampal expression analyses reveal selective association of immediate-early, neuroenergetic, and myelinogenic pathways with cognitive impairment in aged rats.

Rowe WB, Blalock EM, Chen KC, Kadish I, Wang D, Barrett JE, Thibault O, Porter NM, Rose GM, Landfield PW.

J Neurosci. 2007 Mar 21;27(12):3098-110.

4.

Evidence of a role for lactadherin in Alzheimer's disease.

Boddaert J, Kinugawa K, Lambert JC, Boukhtouche F, Zoll J, Merval R, Blanc-Brude O, Mann D, Berr C, Vilar J, Garabedian B, Journiac N, Charue D, Silvestre JS, Duyckaerts C, Amouyel P, Mariani J, Tedgui A, Mallat Z.

Am J Pathol. 2007 Mar;170(3):921-9.

5.

Molecular markers of early Parkinson's disease based on gene expression in blood.

Scherzer CR, Eklund AC, Morse LJ, Liao Z, Locascio JJ, Fefer D, Schwarzschild MA, Schlossmacher MG, Hauser MA, Vance JM, Sudarsky LR, Standaert DG, Growdon JH, Jensen RV, Gullans SR.

Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):955-60. Epub 2007 Jan 10.

6.

A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease.

Tuszynski MH, Thal L, Pay M, Salmon DP, U HS, Bakay R, Patel P, Blesch A, Vahlsing HL, Ho G, Tong G, Potkin SG, Fallon J, Hansen L, Mufson EJ, Kordower JH, Gall C, Conner J.

Nat Med. 2005 May;11(5):551-5. Epub 2005 Apr 24.

PMID:
15852017
7.

Use of within-array replicate spots for assessing differential expression in microarray experiments.

Smyth GK, Michaud J, Scott HS.

Bioinformatics. 2005 May 1;21(9):2067-75. Epub 2005 Jan 18.

PMID:
15657102
8.
9.

Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer's disease.

Reddy PH, McWeeney S, Park BS, Manczak M, Gutala RV, Partovi D, Jung Y, Yau V, Searles R, Mori M, Quinn J.

Hum Mol Genet. 2004 Jun 15;13(12):1225-40. Epub 2004 Apr 28.

PMID:
15115763
10.

fMRI BOLD response to increasing task difficulty during successful paired associates learning.

Gould RL, Brown RG, Owen AM, ffytche DH, Howard RJ.

Neuroimage. 2003 Oct;20(2):1006-19.

PMID:
14568470
11.

Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model.

Kaspar BK, Lladó J, Sherkat N, Rothstein JD, Gage FH.

Science. 2003 Aug 8;301(5634):839-42.

12.

Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits.

Palop JJ, Jones B, Kekonius L, Chin J, Yu GQ, Raber J, Masliah E, Mucke L.

Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9572-7. Epub 2003 Jul 24.

13.

Caspase Activation in the Alzheimer's Disease Brain: Tortuous and Torturous.

Rohn TT, Rissman RA, Head E, Cotman CW.

Drug News Perspect. 2002 Nov;15(9):549-557.

PMID:
12677194
14.

Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease.

Gill SS, Patel NK, Hotton GR, O'Sullivan K, McCarter R, Bunnage M, Brooks DJ, Svendsen CN, Heywood P.

Nat Med. 2003 May;9(5):589-95. Epub 2003 Mar 31.

PMID:
12669033
15.

Neurotrophins: from enthusiastic expectations through sobering experiences to rational therapeutic approaches.

Thoenen H, Sendtner M.

Nat Neurosci. 2002 Nov;5 Suppl:1046-50. Review.

PMID:
12403983
16.

Conservation of neuronal number and size in the entorhinal cortex of behaviorally characterized aged rats.

Merrill DA, Chiba AA, Tuszynski MH.

J Comp Neurol. 2001 Oct 1;438(4):445-56.

PMID:
11559900
17.

Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease.

Price JL, Ko AI, Wade MJ, Tsou SK, McKeel DW, Morris JC.

Arch Neurol. 2001 Sep;58(9):1395-402.

PMID:
11559310
18.

Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment.

Kordower JH, Chu Y, Stebbins GT, DeKosky ST, Cochran EJ, Bennett D, Mufson EJ.

Ann Neurol. 2001 Feb;49(2):202-13.

PMID:
11220740
20.

Conservation of neuron number and size in entorhinal cortex layers II, III, and V/VI of aged primates.

Merrill DA, Roberts JA, Tuszynski MH.

J Comp Neurol. 2000 Jul 3;422(3):396-401.

PMID:
10861515

Supplemental Content

Support Center